Rifaximin-treatment of Collagenous Colitis

Clinical Trials.gov
11 Feb, 2019 ,

An ongoing prospective, randomised, double-blind, placebo-controlled trial conducted by Bonderup, Ole K., M.D in 50 participants aims to evaluate if treatment with Rifaximin for 4 weeks along with a standard treatment protocol can reduce the risk of relapse post treatment cessation in cases of Collagenous Colitis. 

Source